In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.
In a recent video interview with Applied Clinical Trials, Dipanwita Das, CEO & co-founder at Sorcero, discussed advancements and future trends in clinical trials. Key challenges include high costs, long timelines, lack of diversity, and rigid protocols. Das highlighted technological advancements such as AI, real-time monitoring, and historical data analysis, which are all expected to optimize trial design and patient recruitment in 2025 and beyond.
ACT: What types of technology do you think clinical research experts can benefit from the most in their goal of improving patient outcomes?
Das: Technology, of course, is a huge role in transforming all of this, artificial intelligence (AI) certainly, but I think in the next one or two years, trial design optimization is where I'm excited to see the use of more historical data at scale, particularly to optimize inclusion/exclusion criteria, use of AI, and better data science and EHR analysis for patient recruitment, making sure they're actually covering all of the patient populations that need to be represented. Better real-time monitoring: real-time monitoring is just really, really difficult right now, so making sure that there is a certain degree of automated detection of data quality issues, etc., and of course, using AI for literature review protocol writing, as well as automating documentation. In the medium to long term, there are lots of other spaces in which AI and technology overall will play a huge role, from synthetic control arms to adaptive trial designs as well as digital biomarker developments, or even the idea of in silico trials, so there's a lot of exciting things coming up, but I think in the next one to two years, optimizing design, recruiting patients, and real-time monitoring is going to go a long way.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.